Maxigen Biotech Inc. (1783.TW)
TWD 41.6
(-3.03%)
TWD 41.6
(-3.03%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 177.09 Million TWD | 10.4% |
| 2022 | 200.14 Million TWD | 49.82% |
| 2021 | 133.58 Million TWD | 21.35% |
| 2020 | 110.08 Million TWD | 1.38% |
| 2019 | 108.68 Million TWD | 24.08% |
| 2018 | 87.53 Million TWD | 87.87% |
| 2017 | 46.54 Million TWD | 324.57% |
| 2016 | 10.94 Million TWD | 123.06% |
| 2015 | -47.6 Million TWD | -352.6% |
| 2014 | -10.54 Million TWD | -189.47% |
| 2013 | 3.09 Million TWD | 45.37% |
| 2012 | 11.92 Million TWD | 141.16% |
| 2011 | -20.75 Million TWD | -0.06% |
| 2010 | -3.91 Million TWD | -207.58% |
| 2009 | 17.68 Million TWD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 31.84 Million TWD | 4.86% |
| 2024 Q2 | 53.09 Million TWD | 69.66% |
| 2023 Q3 | 62.24 Million TWD | -8.26% |
| 2023 Q1 | 60.28 Million TWD | 1.32% |
| 2023 Q2 | 67.85 Million TWD | 12.54% |
| 2023 FY | - TWD | 10.4% |
| 2023 Q4 | 30.57 Million TWD | -50.89% |
| 2022 Q3 | 60.81 Million TWD | 31.98% |
| 2022 Q1 | 33.75 Million TWD | 35.51% |
| 2022 FY | - TWD | 49.82% |
| 2022 Q4 | 59.5 Million TWD | -2.15% |
| 2022 Q2 | 46.07 Million TWD | 36.49% |
| 2021 Q2 | 30.59 Million TWD | -9.25% |
| 2021 Q4 | 24.91 Million TWD | -43.84% |
| 2021 Q1 | 33.71 Million TWD | -0.11% |
| 2021 FY | - TWD | 21.35% |
| 2021 Q3 | 44.35 Million TWD | 44.97% |
| 2020 Q4 | 33.75 Million TWD | 44.91% |
| 2020 Q1 | 21.86 Million TWD | 20.08% |
| 2020 Q2 | 31.17 Million TWD | 42.59% |
| 2020 Q3 | 23.29 Million TWD | -25.26% |
| 2020 FY | - TWD | 1.38% |
| 2019 Q4 | 18.2 Million TWD | -43.07% |
| 2019 Q3 | 31.97 Million TWD | -25.3% |
| 2019 FY | - TWD | 24.08% |
| 2019 Q1 | 15.59 Million TWD | 6.15% |
| 2019 Q2 | 42.8 Million TWD | 174.52% |
| 2018 Q3 | 25.09 Million TWD | -20.22% |
| 2018 Q2 | 31.45 Million TWD | 104.56% |
| 2018 Q4 | 14.69 Million TWD | -41.46% |
| 2018 FY | - TWD | 87.87% |
| 2018 Q1 | 15.37 Million TWD | 41.45% |
| 2017 Q2 | 17.18 Million TWD | 413.41% |
| 2017 FY | - TWD | 324.57% |
| 2017 Q3 | 15.17 Million TWD | -11.73% |
| 2017 Q1 | 3.34 Million TWD | -67.49% |
| 2017 Q4 | 10.87 Million TWD | -28.36% |
| 2016 Q4 | 10.29 Million TWD | 89.41% |
| 2016 Q2 | 1.39 Million TWD | 122.65% |
| 2016 Q1 | -6.15 Million TWD | 73.43% |
| 2016 Q3 | 5.43 Million TWD | 289.75% |
| 2016 FY | - TWD | 123.06% |
| 2015 Q1 | -9.69 Million TWD | 39.46% |
| 2015 Q2 | -12.14 Million TWD | -25.34% |
| 2015 Q3 | -2.55 Million TWD | 78.95% |
| 2015 Q4 | -23.18 Million TWD | -806.53% |
| 2015 FY | - TWD | -352.6% |
| 2014 FY | - TWD | -189.47% |
| 2014 Q2 | -215 Thousand TWD | -104.49% |
| 2014 Q1 | 4.78 Million TWD | 17.19% |
| 2014 Q4 | -16.01 Million TWD | -1825.22% |
| 2014 Q3 | 928 Thousand TWD | 531.63% |
| 2013 Q1 | 340 Thousand TWD | -17.48% |
| 2013 Q3 | 2.55 Million TWD | -46.45% |
| 2013 Q4 | 4.08 Million TWD | 59.8% |
| 2013 FY | - TWD | 45.37% |
| 2013 Q2 | 4.77 Million TWD | 1303.24% |
| 2012 Q2 | - TWD | 0.0% |
| 2012 Q4 | 412 Thousand TWD | -66.75% |
| 2012 Q3 | 1.23 Million TWD | 0.0% |
| 2012 FY | - TWD | 141.16% |
| 2011 Q4 | - TWD | 0.0% |
| 2011 FY | - TWD | -0.06% |
| 2011 Q2 | - TWD | 0.0% |
| 2010 FY | - TWD | -207.58% |
| 2010 Q4 | - TWD | 0.0% |
| 2009 FY | - TWD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Nang Kuang Pharmaceutical Co., Ltd. | 402.69 Million TWD | 56.023% |
| SciVision Biotech Inc. | 281.34 Million TWD | 37.056% |
| Bionime Corporation | 179.78 Million TWD | 1.495% |
| Pegavision Corporation | 2.91 Billion TWD | 93.931% |
| Visco Vision Inc. | 733.58 Million TWD | 75.859% |